KLRA

Presentations will feature clinical results for ribupatide, a GLP-1/GIP receptor dual agonist being developed as a once-weekly injection and a once-daily oral pill for the treatment of obesity and overweightAdditional data from Phase 2 obesity clinical trial of ribupatide oral demonstrating mean weight loss of up to 12.1% with no observed plateau and up to 38.6% of participants achieving at least 15% weight loss at 26 weeks; incidence of gastrointestinal adverse events was low, with vomiting reported in 11.4% and 7.5% of participants taking 25 mg and 50 mg ribupatide oral, respectivelyPhase 1 single ascending dose trial, the first ribupatide injection clinical data generated outside of China

WALTHAM, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (NASDAQ:KLRA), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced that Ron Renaud, President and Chief Executive Officer, will present at the 2026 Jefferies Global Healthcare Conference on Thursday, June 4, at 10:30 am EDT. A live webcast will be available on the Events page of Kailera's investor website. A replay of the conference webcast will be archived on the company's website for 90 days. About Kailera Therapeutics Kailera Therapeutics (Kailera) is a clinical-stage biotechnology company focused on elevating the next era of obesity care by progressing a

10-Q - Kailera Therapeutics, Inc. (0002096997) (Filer)

8-K - Kailera Therapeutics, Inc. (0002096997) (Filer)

Important progress across four clinical-stage programs demonstrating depth and breadth of obesity pipeline Initiated five late-stage global clinical trials in obesity, including the ribupatide injection KaiNETIC Phase 3 programReported positive topline clinical data from three trials conducted by our partner Hengrui in China, including new topline data from Phase 3 trial of oral small molecule GLP-1 receptor agonist HRS-7535 (KAI-7535) in type 2 diabetes, and first-in-human topline data from Phase 1 trial for injectable tri-agonist HRS-4729 (KAI-4729)Cash on hand, including IPO proceeds, is expected to fund operations into mid-2028 WALTHAM, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Kailera

SHANGHAI and WALTHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Hengrui Pharma (Hengrui), a global pharmaceutical company focused on scientific and technological innovation, and Kailera Therapeutics, Inc. (Kailera), an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the presentation of two abstracts at the 86th Scientific Sessions of the American Diabetes Association (ADA), taking place June 5–8, 2026 in New Orleans, Louisiana. The presentations will feature clinical results for oral and injectable ribupatide, a GLP-1/GIP receptor dual agonist, highlighting the potential of the ribupatide franchise to deliver potentially differ

Analyst initiated coverage of Kailera Therapeutics with a rating of Overweight and set a new price target of $30.00

William Blair initiated coverage of Kailera Therapeutics with a rating of Outperform

Leerink Partners initiated coverage of Kailera Therapeutics with a rating of Outperform and set a new price target of $36.00

TD Cowen initiated coverage of Kailera Therapeutics with a rating of Buy and set a new price target of $57.00

Evercore ISI initiated coverage of Kailera Therapeutics with a rating of Outperform

Jefferies initiated coverage of Kailera Therapeutics with a rating of Buy and set a new price target of $48.00

SCHEDULE 13D - Kailera Therapeutics, Inc. (0002096997) (Subject)

SCHEDULE 13D - Kailera Therapeutics, Inc. (0002096997) (Subject)

4 - Kailera Therapeutics, Inc. (0002096997) (Issuer)

4 - Kailera Therapeutics, Inc. (0002096997) (Issuer)

SHANGHAI, April 22, 2026 /PRNewswire/ -- Hengrui Pharma reported steady growth in the first quarter of 2026. In Q1 2026, the Company recorded revenue of RMB 8.14 billion, up 12.98% year-over-year, while net profit attributable to shareholders increased by 21.78% to RMB 2.28 billion. Innovative drugs remained the key growth driver, generating RMB 4.53 billion in revenue, up 25.75% year-over-year and accounting for 61.69% of total pharmaceutical sales. The Company continued to advance its innovation-driven strategy with sustained R&D investment and solid pipeline progress. R&D investments in Q1 2026 totaled RMB 2.22 billion, representing for approximately 27.32% of revenue.During the period, t

4 - Kailera Therapeutics, Inc. (0002096997) (Issuer)

4 - Kailera Therapeutics, Inc. (0002096997) (Issuer)

4 - Kailera Therapeutics, Inc. (0002096997) (Issuer)

4 - Kailera Therapeutics, Inc. (0002096997) (Issuer)

4 - Kailera Therapeutics, Inc. (0002096997) (Issuer)

4 - Kailera Therapeutics, Inc. (0002096997) (Issuer)

4 - Kailera Therapeutics, Inc. (0002096997) (Issuer)

4 - Kailera Therapeutics, Inc. (0002096997) (Issuer)